Forecasting cytokine storms with new predictive biomarkers

Cancer Discovery

Volumn 6, Issue 6, 2016, Pages 579-580

  Rouce, Rayne H ^a,b   Heslop, Helen E ^a  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD19 ANTIBODY; GAMMA INTERFERON; INTERLEUKIN 6; TOCILIZUMAB; TUMOR NECROSIS FACTOR; CD19 ANTIGEN; CYTOKINE; LYMPHOCYTE ANTIGEN RECEPTOR;

ARTICLE; CYTOKINE RELEASE SYNDROME; CYTOKINE STORM; DISEASE SEVERITY; EARLY DIAGNOSIS; HUMAN; MOLECULARLY TARGETED THERAPY; MORBIDITY; MORTALITY; TREATMENT RESPONSE; IMMUNOLOGY; T LYMPHOCYTE;

ANTIGENS, CD19; BIOMARKERS; CYTOKINES; HUMANS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 85011961068     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-16-0493     Document Type: Article

References (9)

1. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014;371:1507-17.
2. Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014;6:224ra25.
3. Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 2015;385:517-28.
4. Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 2015;33:540-9.
5. +composition in adult B cell ALL patients. J Clin Invest 2016 Apr 25 [Epub ahead of print].
6. Papadopoulou A, Krance RA, Allen CE, Lee D, Rooney CM, Brenner MK, et al. Systemic inflammatory response syndrome after administration of unmodified T lymphocytes. Mol Ther 2014;22:1134-8.
7. Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 2014;124:188-95.
8. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013;368:1509-18.
9. Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Maude SL, Frey N, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov 2016;6:664-79.